Tenaya Therapeutics, INC

Tenaya Therapeutics announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, succeeding Faraz Ali and Tomohiro Higa in interim roles.

Tenaya Therapeutics stockholders approved an amended 2021 Equity Incentive Plan and re-elected three Class II directors at the 2026 Annual Meeting.

Tenaya Therapeutics reported Q1 2026 financial results, highlighting progress in its gene therapy programs for genetic cardiomyopathies and a new research collaboration with Alnylam.

Tenaya Therapeutics has entered a significant collaboration with Alnylam Pharmaceuticals to discover and validate novel gene targets for cardiovascular disease, potentially worth over $1.1 billion.

Tenaya Therapeutics received a Nasdaq notice for failing to meet the minimum bid price requirement, while also expanding its equity incentive plan to attract new talent.

David Goeddel has voluntarily resigned from Tenaya Therapeutics' Board of Directors, effective January 26, 2026, due to retirement.

Tenaya Therapeutics reports on clinical trial advancements for TN-201 and TN-401, alongside a net loss of $19.3 million for Q1 2026.

Tenaya Therapeutics reported reduced net losses in Q3 2025, driven by cost-cutting, but its lead gene therapy TN-201 was placed on clinical hold by the FDA.

Tenaya Therapeutics reported a reduced net loss in Q2 2025, driven by cost containment and a recent follow-on offering, as it advances its lead gene therapy candidates for heart disease.

Tenaya Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and cost containment measures.

Tenaya Therapeutics, a clinical-stage biotechnology company, released its third quarter 2024 results, highlighting progress in its gene therapy programs and providing an update on its financial status.

Tenaya Therapeutics reports a net loss of $29.4 million for the second quarter of 2024, alongside updates on clinical programs and cost-saving initiatives.

Tenaya Therapeutics' 10-K filing summarizes the company's focus on developing gene therapies for heart disease, clinical trial progress, and financial position for the year ended December 31, 2024.

Tenaya Therapeutics' 10-K filing details its progress in developing gene and small molecule therapies for heart disease, including updates on clinical trials and manufacturing capabilities.

Eric J Hyllengren, Chief Financial Officer of Tenaya Therapeutics, Inc., received 1,650,000 shares of common stock on July 13, 2026.

Director Williams R. Sanders was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Director Jeffrey T. Walsh was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Director Catherine Stehman-Breen was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Director Deepak Srivastava was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Director Karah Herdman Parschauer was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Tenaya Therapeutics has filed its 2026 proxy statement, seeking stockholder approval for director elections, auditor ratification, and an amendment to its 2021 Equity Incentive Plan.

Tenaya Therapeutics will hold its annual stockholders meeting on May 28, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Tenaya Therapeutics will hold its annual stockholders meeting virtually on May 28, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Tenaya Therapeutics will hold its annual stockholders meeting on May 30, 2024, to elect directors and ratify the appointment of its independent auditor.

Tenaya Therapeutics will hold its annual meeting of stockholders virtually on May 30, 2024, to elect directors and ratify the appointment of its independent accounting firm.

The Column Group entities report significant sales of Tenaya Therapeutics common stock, reducing their overall exposure.

The Column Group entities, including managing partners Tim Kutzkey and Peter Svennilson, reported significant sales of Tenaya Therapeutics common stock in early February 2026.

The Column Group's aggregate ownership in Tenaya Therapeutics has decreased by over 1% due to the issuer's recent sales of additional common stock.

The Column Group and its affiliated funds have updated their beneficial ownership in Tenaya Therapeutics, Inc., reporting a decrease in their aggregate percentage stake due to the issuer's recent share sales.

Casdin Capital and its affiliates have filed their final Schedule 13D amendment for Tenaya Therapeutics, Inc., indicating they no longer beneficially own more than 5% of the company's common stock.

The Column Group entities have significantly increased their beneficial ownership in Tenaya Therapeutics, Inc. to 32.0% following a $25 million investment in the company's recent public offering.

Woodline Partners LP has disclosed a 4.99% beneficial ownership stake in Tenaya Therapeutics, Inc., primarily through warrants subject to a 4.99% ownership blocker.

Empery Asset Management, LP, along with Ryan M. Lane and Martin D. Hoe, reported a 4.99% beneficial ownership stake in Tenaya Therapeutics, Inc., including shares issuable from warrants, subject to a 4.99% ownership cap.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.7% beneficial ownership stake in Tenaya Therapeutics, Inc. as of June 30, 2025.

Woodline Partners LP has filed a Schedule 13G, revealing a beneficial ownership of 6.8% in Tenaya Therapeutics, Inc.'s common stock as of March 31, 2025.

Empery Asset Management, LP, along with Ryan M. Lane and Martin D. Hoe, has disclosed a collective beneficial ownership of 9.96% in Tenaya Therapeutics, Inc. as of March 31, 2025.

JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a beneficial ownership of 2.8% in Tenaya Therapeutics, Inc.'s common stock as of February 28, 2025.